New York, June 3, 2024—Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new clinical uses for VitaGraft Kidney, including therapeutic...
![Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte’s VitaGraft Study](https://prismmediawire.com/wp-content/uploads/2024/06/Newsroom.png)